Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ：a Single Arm, Open Label, Multi-center Phase II Study

NCT04989621 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04989621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) ：a Single Arm, Open Label, Multi-center Phase II Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2021
Completion date
August 31, 2028
Enrollment
32 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, relapsed and refractory follicular lymphoma